Ferritin Nanoparticle Cancer Vaccine Boosts Immune Response to Neoantigen Peptides
Recombinant ferritin nanoparticles carrying neoantigen peptides significantly enhanced anti-tumor immune responses compared to free peptides, improving cancer vaccine effectiveness.
Quick Facts
What This Study Found
Ferritin-based nanoparticles significantly enhanced neoantigen-specific immune responses compared to free peptide delivery, improving anti-tumor T cell activation.
Key Numbers
Neoantigen-FN nanoparticles successfully activated antigen-specific T cells and inhibited both tumor growth and metastasis.
How They Did This
Engineered recombinant ferritin nanoparticles displaying neoantigen peptides. Compared immune responses to free peptides vs ferritin-displayed peptides in tumor models. Assessed T cell activation, tumor infiltration, and anti-tumor efficacy.
Why This Research Matters
Neoantigen cancer vaccines are one of the most promising immunotherapy approaches but have been limited by weak immune activation. A simple nanoparticle carrier that amplifies the response could make personalized cancer vaccines practical.
The Bigger Picture
Ferritin is a naturally occurring protein that self-assembles into cage-like nanoparticles, already used in vaccine development (including COVID-19 candidates). Repurposing this platform for cancer neoantigen delivery combines proven nanotechnology with personalized oncology.
What This Study Doesn't Tell Us
Preclinical study in animal tumor models. Manufacturing patient-specific ferritin-neoantigen particles at scale remains challenging. Not all neoantigens may display well on ferritin surfaces.
Questions This Raises
- ?Can ferritin-neoantigen vaccines be manufactured quickly enough for individual patients?
- ?How many neoantigens can be displayed on a single ferritin particle?
- ?Would combining ferritin-neoantigen vaccines with checkpoint inhibitors improve cure rates?
Trust & Context
- Key Stat:
- Stronger immunity Ferritin nanoparticles displaying neoantigen peptides significantly enhanced anti-tumor T cell responses compared to free peptides alone
- Evidence Grade:
- Preliminary evidence: preclinical study demonstrating improved immune activation with nanoparticle delivery of cancer neoantigen peptides.
- Study Age:
- Published in 2024. Advances the intersection of nanotechnology and cancer immunotherapy.
- Original Title:
- Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.
- Published In:
- Journal of nanobiotechnology, 22(1), 562 (2024)
- Authors:
- Zheng, Wei(4), Li, Shixiong, Shi, Zhongliang, Su, Kailing, Ding, Yu, Zhang, Luyue, Tang, Qian, Han, Jiani, Zhao, Han, Wang, Fengwei, Zhang, Hongru, Hong, Zhangyong
- Database ID:
- RPEP-09674
Evidence Hierarchy
Frequently Asked Questions
What is a ferritin nanoparticle?
Ferritin is a natural iron-storage protein that self-assembles into tiny cage-like structures (12-24 nm). Researchers can attach peptides to the surface, creating nanoparticles that are well-recognized by the immune system and safe for vaccine use.
How does this improve cancer vaccines?
Free peptide vaccines often generate weak immune responses. By displaying neoantigen peptides on ferritin nanoparticles, the immune system recognizes them more efficiently, producing stronger anti-tumor T cell responses.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09674APA
Zheng, Wei; Li, Shixiong; Shi, Zhongliang; Su, Kailing; Ding, Yu; Zhang, Luyue; Tang, Qian; Han, Jiani; Zhao, Han; Wang, Fengwei; Zhang, Hongru; Hong, Zhangyong. (2024). Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.. Journal of nanobiotechnology, 22(1), 562. https://doi.org/10.1186/s12951-024-02837-2
MLA
Zheng, Wei, et al. "Recombinant ferritin-based nanoparticles as neoantigen carriers significantly inhibit tumor growth and metastasis.." Journal of nanobiotechnology, 2024. https://doi.org/10.1186/s12951-024-02837-2
RethinkPeptides
RethinkPeptides Research Database. "Recombinant ferritin-based nanoparticles as neoantigen carri..." RPEP-09674. Retrieved from https://rethinkpeptides.com/research/zheng-2024-recombinant-ferritinbased-nanoparticles-as
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.